Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

TG Therapeutics, Inc. (NKB2.F)

Compare

32.37

-1.07

(-3.20%)

As of 12:10:05 PM GMT+1. Market Open.

Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 13% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves examining companies that demonstrate strong potential for expansion and innovation amidst these dynamic market conditions.

Simply Wall St. 7 hours ago

WAY

EXEL

TGTX
Why TG Therapeutics, Inc. (TGTX) Surged On Monday?

We recently published a list of 10 Stocks Lead Monday’s Charge Amid Market Bloodbath. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other stocks that lead Monday’s charge amid market bloodbath. The stock market kicked off the trading week in a bloodbath, erasing last week’s […]

Insider Monkey 8 hours ago

TGTX
Company News for Mar 4, 2025

Companies In The News Are: CRC, TGTX, NOMD, BHVN.

Zacks 10 hours ago

TGTX

CRC

NOMD
TG Therapeutics Inc (TGTX) Q4 2024 Earnings Call Highlights: Strong U.S. ...

TG Therapeutics Inc (TGTX) reports robust financial performance with significant growth in BRIUMVI sales and outlines ambitious plans for 2025.

GuruFocus.com 11 hours ago

TGTX
Q4 2024 TG Therapeutics Inc Earnings Call

Q4 2024 TG Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 13 hours ago

TGTX
TG Therapeutics soared 17% after earnings surprise

Here’s what happened to TG Therapeutics.

TheStreet 20 hours ago

TGTX
TG Therapeutics, A New Leaderboard Stock, Skyrockets 14% On Sales Beat, Bullish Guide

TG Therapeutics stock skyrocketed Monday after easily beating fourth-quarter sales expectations and issuing a bullish outlook for 2025.

Investor's Business Daily 21 hours ago

TGTX
Meta, Netflix Hold Tough As Tech Tanks. This Biotech Booms.

While Netflix and Meta stock fight to shake off market volatility, Eli Lilly and this biotech stock join them and others on IBD Leaderboard.

Investor's Business Daily 21 hours ago

LLY

META

NFLX
TG Therapeutics Soars Nearly 18% as Strong Q4 Results Fuel Growth Optimism

Biopharma firm TG Therapeutics sees stock surge as revenue beats estimates and plans for new Briumvi trial take shape

GuruFocus.com yesterday

TGTX
TG Therapeutics (NasdaqCM:TGTX) Reports US$108M Revenue For Q4 2024 With Net Income Of US$23M

TG Therapeutics (NasdaqCM:TGTX) reported a 3.7% increase in its stock price over the last week, coinciding with the company's announcement of strong fourth-quarter earnings results and optimistic earnings guidance for 2025. The company revealed a significant jump in revenue to $108 million and a transition to profitability, posting a net income of $23 million for Q4 2024. The positive outlook, particularly for its BRIUMVI product, was emphasized in their earnings guidance, projecting...

Simply Wall St. yesterday

TGTX
TG Therapeutics: Q4 Earnings Snapshot

On a per-share basis, the Morrisville, New York-based company said it had net income of 15 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 8 cents per share.

Associated Press Finance yesterday

TGTX
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Fourth quarter and full year 2024 BRIUMVI U.S. net revenue of $103.6 million and $310 million, respectively Target guidance of approximately $540 million in total global revenue for 2025 Conference call to be held today, March 3, 2025, at 8:30 AM ET NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and full year ended December 31, 2024, along with recent company developme

GlobeNewswire yesterday

TGTX
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida. Links to each presentation are included below. Michael S. Weiss, C

GlobeNewswire 5 days ago

TGTX
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Conference call to be held Monday, March 3, 2025, at 8:30 AM ETNEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1

GlobeNewswire 6 days ago

TGTX
Institutional investors in TG Therapeutics, Inc. (NASDAQ:TGTX) see US$243m decrease in market cap last week, although long-term gains have benefitted them.

Key Insights Significantly high institutional ownership implies TG Therapeutics' stock price is sensitive to their...

Simply Wall St. 7 days ago

TGTX
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) to be presented at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 27 – March 1, 2025, in West Palm Beach,

GlobeNewswire 14 days ago

TGTX
How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months

TG Therapeutics CEO Michael Weiss says his biotech company is small, but "mighty." But TG stock's move has been anything but small.

Investor's Business Daily 20 days ago

TGTX
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy

TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

TGTX
Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX)

We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against the other hot stocks. What’s the US Stock Market Like in 2025? While the stock market in the United States remained closed […]

Insider Monkey last month

TGTX
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has dropped 1.2%, yet it remains up by 23% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves focusing on companies that can sustain robust revenue expansion and innovation despite short-term market fluctuations.

Simply Wall St. last month

BTDR

CLBT

CLBTW

Performance Overview

Return	NKB2.F	S&P 500
YTD	+4.62%	-1.15%
1-Year	+97.98%	+13.31%
3-Year	+288.78%	+34.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TG Therapeutics, Inc. (NKB2.F)

Exploring 3 High Growth Tech Stocks In The US Market

Why TG Therapeutics, Inc. (TGTX) Surged On Monday?

Company News for Mar 4, 2025

TG Therapeutics Inc (TGTX) Q4 2024 Earnings Call Highlights: Strong U.S. ...

Q4 2024 TG Therapeutics Inc Earnings Call

TG Therapeutics soared 17% after earnings surprise

TG Therapeutics, A New Leaderboard Stock, Skyrockets 14% On Sales Beat, Bullish Guide

Meta, Netflix Hold Tough As Tech Tanks. This Biotech Booms.

TG Therapeutics Soars Nearly 18% as Strong Q4 Results Fuel Growth Optimism

TG Therapeutics (NasdaqCM:TGTX) Reports US$108M Revenue For Q4 2024 With Net Income Of US$23M

TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Institutional investors in TG Therapeutics, Inc. (NASDAQ:TGTX) see US$243m decrease in market cap last week, although long-term gains have benefitted them.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months

All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy

Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX)

Exploring Three High Growth Tech Stocks In The United States

Performance Overview